Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.64 |
| ▸ | BCL2 | P10415 | 16/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 10/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951472 | 0.87 | BCL2L1 (0.64) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL2943772 | 0.86 | BCL2L1 (0.62) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL2944685 | 0.83 | BCL2L1 (0.65) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL2947910 | 0.83 | BCL2L1 (0.60) | BCL2L1BCL2MCL1 | |
| SCHEMBL2952759 | 0.82 | BCL2L1 (0.90) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL2948480 | 0.81 | BCL2L1 (0.71) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL2950775 | 0.80 | BCL2L1 (0.70) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL2951813 | 0.80 | BCL2L1 (0.68) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL2949198 | 0.79 | BCL2L1 (0.67) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL2944351 | 0.79 | BCL2L1 (1.00) | BCL2L1BCL2MCL1AURKAPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885MCL1 14/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885BCL2 3/4885MCL1 11/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885MCL1 14/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | BCL2L1 6/4885BCL2 2/4885MCL1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.